Advertisement

Topics

Alnylam Pharmaceuticals Company Profile

17:24 EST 18th December 2018 | BioPortfolio

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a wide array of important diseases.
Founded by leading scientists who pioneered the discovery of RNAi, Alnylam is developing technology with the potential to specifically and potently silence disease-causing genes. RNA interference is a natural cellular process for selectively turning off the activity of genes by targeting RNA, the key intermediate between DNA and proteins. By harnessing this natural process, Alnylam is developing novel therapeutics that will utilize the natural RNAi mechanism to selectively suppress genes that produce proteins that play harmful roles in disease.

Alnylam is uniquely positioned to leverage the full potential of RNAi for therapeutic applications. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Alnylam Europe of Kulmbach, Germany. The company's leading position in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how relating to RNAi. These patents and patent applications broadly cover compositions, methods and uses of small interfering RNAs or siRNAs, the molecules that mediate RNAi. Alnylam's IP estate has been leveraged today with licenses to numerous companies for therapeutic and research market applications. Alnylam has assembled an experienced management team, strong financial resources, and world class collaborators to build a pipeline of RNAi therapeutics using both Direct RNAiTM and Systemic RNAiTM approaches. Alnylam has formed major alliances with Merck, Medtronic and Novartis.

Location

300 Third Street, 3rd Floor
Cambridge
2142
United States of America

Contact

Phone: 617-551-8200
Fax: 617-551-8101


News Articles [481 Associated News Articles listed on BioPortfolio]

Alnylam Announces Submission Of NDA In Japan For ONPATTRO

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced it has submitted a New Drug Application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency for approval of patisiran ...

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

A few weeks ago, Alnylam Pharmaceuticals indicated it might seek a speedy FDA approval for what could be the second-ever RNA interference medicine to market. After meeting with regulators, however, th...

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

Alnylam Pharmaceuticals was just cleared to market the first-ever RNA interference medicine. The second one may not be that far behind. Alnylam (NASDAQ: ALNY), of Cambridge, MA, said this morning that...

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

[Updated at 3:25 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon. The FDA has just approved Alnylam’s patisiran (Onpattro), making it the first medicine specifically cleared to...

EC OKs Alnylam's hereditary transthyretin-mediated amyloidosis drug

Alnylam Pharmaceuticals' Onpattro, or patisiran, was approved by the European Commission as a treatment for adult patients wi -More- 

U.K. Agency Grants Early Access To Alnylam's Patisiran

NewsPatisiran is an investigational RNAi therapeutic in development for the treatment of hATTR amyloidosis. Contributed Author: 

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran

NewsLumasiran treatment resulted in 75 percent mean maximal reduction in urinary oxalate relative to baseline.Contributed Author: 

Alnylam files for early approval of givosiran

Alnylam Pharmaceuticals has filed for accelerated approval from the FDA for its drug givosiran after a successful clinical tr -More- 

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]

EYEWASH STATION ADDITIVE CONCENTRATE

PubMed Articles [128 Associated PubMed Articles listed on BioPortfolio]

Alnylam launches era of RNAi drugs.

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Clinical Trials [228 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1342 Associated Companies listed on BioPortfolio]

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. and The Medicines Company

Alnylam Pharmaceuticals, Inc.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a ...

More Information about "Alnylam Pharmaceuticals" on BioPortfolio

We have published hundreds of Alnylam Pharmaceuticals news stories on BioPortfolio along with dozens of Alnylam Pharmaceuticals Clinical Trials and PubMed Articles about Alnylam Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Pharmaceuticals Companies in our database. You can also find out about relevant Alnylam Pharmaceuticals Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record